INOVIO PHARMACEUTICALS, INC. - 8-K Filing
Inovio Pharmaceuticals receives FDA accelerated approval for VOCERYQ™ to reduce surgery frequency in adults with Recurrent Respiratory Papillomatosis (RRP). (Items: 7.01 Regulation FD Disclosure, 8.01 below, on October 30, 2026, Inovio Pharmaceuticals, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $INO
Read the full article at SEC EDGAR
Part of the story Phathom Pharmaceuticals, Inc. - 10-Q Filing (11 articles)